These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 20359839
1. Efficacy and tolerability of levetiracetam in children with epilepsy. Li J, Xiao N, Chen S. Brain Dev; 2011 Feb; 33(2):145-51. PubMed ID: 20359839 [Abstract] [Full Text] [Related]
5. Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. Obeid M, Pong AW. Epilepsy Res; 2010 Sep; 91(1):101-5. PubMed ID: 20663645 [Abstract] [Full Text] [Related]
6. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. Giroux PC, Salas-Prato M, Théorêt Y, Carmant L. Seizure; 2009 Oct; 18(8):559-63. PubMed ID: 19546014 [Abstract] [Full Text] [Related]
7. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. Li S, Cao J, Xiao N, Cai F. J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208 [Abstract] [Full Text] [Related]
8. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. Perry S, Holt P, Benatar M. J Child Neurol; 2008 May; 23(5):515-9. PubMed ID: 18182645 [Abstract] [Full Text] [Related]
9. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Peake D, Mordekar S, Gosalakkal J, Mukhtyar B, Buch S, Crane J, Wheway R, Rittey C, Donnelly J, Whitehouse WP, Philip S. Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474 [Abstract] [Full Text] [Related]
10. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Grosso S, Cordelli DM, Franzoni E, Coppola G, Capovilla G, Zamponi N, Verrotti A, Morgese G, Balestri P. Seizure; 2007 Jun; 16(4):345-50. PubMed ID: 17368928 [Abstract] [Full Text] [Related]
11. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP. Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325 [Abstract] [Full Text] [Related]
12. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400 [Abstract] [Full Text] [Related]
19. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Coppola G, Mangano S, Tortorella G, Pelliccia A, Fels A, Romano A, Nardello R, Habetswallner F, Licciardi F, Operto FF, Pascotto A. Epilepsy Res; 2004 Mar; 59(1):35-42. PubMed ID: 15135165 [Abstract] [Full Text] [Related]
20. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study. Peltola J, Peltola M, Auvinen A, Keränen T, Liimatainen S, Kharazmi E, Fallah M. Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915 [Abstract] [Full Text] [Related] Page: [Next] [New Search]